ABSTRACT
INTRODUCTION
Motivated behaviours are basically maintained by Wakefulness and vigilance levels. Orexins -a pair of neuropeptides that are essential for maintaining wakefulness -were also involved in the regulation of motivated behaviors such as feeding and drinking and implicated in emotional aspects. 1 Orexin A and Orexin B are primarily identified in the lateral hypothalamus, the classical feeding center. 2 Their receptors, OX1 and OX2 have been expressed in several places in the brain. 3 Moderate numbers of Orexin fibres were located in medial Nucleus Accumbens (NAc). 4 NAc is implicated in motivated behaviours like feeding and drinking via dopamine receptors. 5, 6 It was reported that the Orexin system regulates central motor control. 7 Infusion of Orexin A into paraventricular nucleus of hypothalamus augmented the impulsive physical exploratory activity in rats, whereas OX 1 R antagonist SB334867 significantly attenuated such effects. 8 Orexin A infusion into the rostral lateral part of hypothalamus, NAc 9 and locus coeruleus increased locomotor activity in rats. 10 Orexin A induced firing in local coeruleus, indicated potential involvement of Orexin in maintaining arousal. We earlier demonstrated that Orexin B infusion into Nucleus Accumbens increased exploratory behaviour, but not anxiety like behaviour. 11 This was proved by inhibition of this activity by Orexin B antagonist (TCS-OX2-29), which decreased exploratory behaviour significantly, whereas anxiety behaviour was unaffected. Dopamine action in the Nucleus Accumbens has been implicated in motivated behaviours. 12 Further dopamine antagonist suppressed increased locomotor activity by Orexins in Rodents. 13 Role of glutamate in Orexin A induced motivated behaviour is also well established.
14 Role of serotonergic system in the Orexin infused locomotor behaviour is also demonstrated. 15 Studies indicate that noradrenaline transmission increases locomotor activity. 16 Yet data on Orexin induced catecholaminergic pathway in exploratory behaviour is unclear. Hence in the present study was designed to investigate if the alteration in exploratory behaviour by Orexin B and its antagonist is due to adrenergic and/or noradrenergic activity in Nucleus Accumbens. To explore the possible mechanism involved in Orexin B mediated exploratory behaviour standard biochemical analysis of adrenaline and noradrenaline in Nucleus Accumbens were conducted immediately after the experimental session.
MATERIALS AND METHODS
A total of 48 male albino Wistar rats of 3-4 months old (200-275gms) were housed separately in poly-propylene cages (29cms x 22cms x 14cms) with bedding of paddy husk, under normal day-night cycle in temperature controlled room during the experimental period. Food pellets (procured from Pranav Agro Industries Ltd, Maharashtra, India) and potable tap water were available to animals ad. Lib. (except in the groups as mentioned in the experimental requirement). Animals were divided into Group I (Control) Group II (Orexin B) and Group III (Oexin B antagonist) with 6 animals each.
Animals were done according to the notifications by Government of India. (Government of India gazette notification, Dec 15, 1998.) . Prior to the initiation of the study Institutional Animal Ethical Committee (I.A.E.C) (KMC/57/2009-2010) consent was obtained.
METHODOLOGY

Surgical procedure and cannulation
A combination of Ketamine (50 mg/ml) and Xylazine (20 mg/ml) were used to anesthetize the rats. Calculated volume of anesthetic agents was drawn from the vials to make a solution containing the equivalent of 70 mg/kg bwtt of Ketamine and 10 mg/kg body weight of Xylazine and injected by i.p. route. Stereotaxic surgical procedure and implantation of cannula was done according to our previously published work. 17, 18, 19 Micro infusion procedure Orexin B (30nanomol/µl) (Catalog no. 06262 Sigma Aldrich, St Louis, USA) was administered bilaterally into the specific nuclei in separate groups of rats. 20 TCS-OX2-29 (Catalog.No.3370; Tocris Bioscience, UK), a Orexin B antagonist, was dissolved in 0.9% saline and injected at a dose of 10 micrograms/µl in separate groups of rats. 17 Sham controls with the surgical procedure and injected with 0.9% saline. The infusion Orexin B and TCS-OX2-29 was performed according to the methodology published in the earlier work of current laboratory. 6 Rats were made to fast for a day prior to drug infusion. Four trials of Orexin B infusion was carried out. 72 h intervened between consecutive treatment days. Open field exploration test was carried out as described earlier.
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Estimation of neurotransmitters Dissection of discrete regions of the brain
Sample collection was done next day of the fourth trial of Orexin B/ antagonist infusion into the Nucleus Accumbens and BLA. Rat brain was removed soon after sacrifice of the rats by decapitation. The dorsal portion of the cranium was peeled off by bone cutter and by means of blunt forceps brain was placed into ice-cold glass plate excluding the olfactory bulbs. Coronal sections of 1mm thickness were made in rat brain slicer and were mounted on glass slide. Nucleus Accumbens and Basolateral amygdala were quickly dissected out on a chilled petridish placed on crushed ice.
Tissue preparation
The freshly prepared brain sample on thin aluminium foil, was freezed and stored immediately at -70°C or deeper until subsequent preparation. At the day of homogenization the wet weight of the sample (NAc and BLA) was estimated and transferred it into ice cooled solution containing 0.1 N Hcl and 1 mmol EDTA (1 ml/ 50 mg wet weight brain tissue). Centrifugation of the sample was done at 15,000 g for 15 min at 4°C and the supernatant were used for ELISA analysis. Noradrenaline and adrenaline were estimated by Tricat ELISA kit (IBL, Germany catalogue number.RE-59395). The optical density (OD) was measured using Bio Tek EL X -800 automated ELISA micro plate reader.
Statistical analysis
Data is represented as mean±SEM. One way ANOVA followed by Student-Newman Keuls test was used. (SPSS version.16.0.) p < 0.05 was considered significant.
RESULTS
Effect of micro infusion of orexin B and TCS-OX2-29 into Nucleus Accumbens on adrenaline and noradrenaline in Openfield exploration test
The infusion of orexin B into Nucleus Accumbens made significantly more (p<0.001) central square entries compared to controls (Figure 1 ). There was also a significant increase (p<0.001) in time spent in central squares compared to controls (Figure 2 ). Nucleus Accumbens infused group didn't show any alteration in the number of rearings, (p>0.05) grooming (p>0.05) and fecal excreta (p>0.05) (Figure 3 Unequivocal evidence for the orexinergic output mediation through the noradrenergic neurons was observed by infusion of orexin antagonist TCS-OX2-29 into the NAc, resulted in significant decrease in noradrenaline levels in the present study. In TCS-OX2-29 infused rats open field exploration activity was reduced. (Table 1 ). However, Adrenaline was not significantly altered with Orexin B antagonist infusion. Earlier reports from the our laboratory revealed that micro infusion of Orexin B antagonist (TCS-OX2-29) into NAc induced significantly fewer central squares entries and significantly less time spent when compared to controls. 11 Infusion in Orexin B antagonist didn't alter no of grooming, rearing and fecal boli excreted significantly which is an indicative of anxiety like behaviour.
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Findings of the present study reveal the significant increase noradrenaline levels in Orexin B infused rats after open field exploration test (Table 1) . Similarly adrnaline was decreased with TCS-OX2-29 infusion. However, Adrenaline was not significantly altered with Orexin B and its antagonist infusion. Li and Vanden Pol reported that Orexin of hypothalamic origin increases arousal which is also a action of noradrenaline. 22 It was documented that Orexin A potentiated the contraversive pivoting. This was due to the activation of the dopamine receptors in the shell of NAc. Orexin A antagonist SB334867 did not affect the pivoting. 23 Since discovery of Orexins in 1998, evidence for its role in arousal has been enormous. Studies reinforced OX's role in promoting arousal and wakefulness. 24 Studies also demonstrate the role of OX in the regulation of a variety of emotional behaviour. 25 Noradrenergic transmission is directly associated with exploratory behaviour and novelty. 26 The observed exploratory behaviour in the present study could be due to noradrenergic activity in Nucleus Accumbens. It has long been reported that Noradrenaline in Nucleus Accumbens stimulates locomotor behaviour in rats. 27 It has also been reported that Orexins activate the neurons containing noradrenaline. 28 Another study reported that both Orexin peptides release noradrenaline from cerebrocortical slices. 29 Noradrenaline is one of the important neurotransmitter involved in arousal and sleep wake regulation. Norepinephrine through the ascending arousal system impacts sleep wake cycle. 30 It is also reported that norepinephrine and locus coeruleus system integrated to regulate sleep and waking. 31 Orexins also play an important physiological role in maintaining sleep-wake cycle. 32 In the present study Orexin B infusion Summary of open field in Orexin B and antagonist infused rats in Nucleus Accumbens.
Note :Graph is reproduced from results presented in our previous article published from our lab11
DISCUSSION
The nature of relationship between neuropeptides Orexin and arousal remains poorly understood. 19 The earlier reports from our laboratory proved that Orexin B infusion into Nucleus Accumbens stimulates exploratory behaviour. 11 In our previous study, infusion of Orexin B into NAc induced significantly more central square entries in injected rats when compared to controls. 11 There was also a significant increase in time spent in central squares compared to controls. 11 Findings of the present study reveal the significant increase noradrenaline levels in Orexin B infused rats after open field exploration test (Table 1) . However, Adrenaline was not significantly altered with Orexin B infusion. Thorpe et al reported earlier that Orexin A infusion into NAc Shell increases locomotor activity in to Nucleus Accumbens increases locomotor activity through noradrenergic system. This gives further evidence for the relationship between orexinergic and noradrenergic system. We unequivocally prove that Orexin-noradrenergic system in Nucleus Accumbens stimulate locomotor activity and motivated behaviour.
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